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Evidence indicates an intimate connection between the neuroendocrine and the immune 
systems. A number of in vitro and in vivo studies have demonstrated growth hormone 
(GH) involvement in immune regulation. The GH receptor is expressed by several leuko-
cyte subpopulations, and GH modulates immune cell proliferation and activity. Here, we 
found that sustained GH expression protected against collagen-induced arthritis (CIA); 
in GH-transgenic C57BL/6 (GHTg) mice, disease onset was delayed, and its overall 
severity was decreased. The anti-collagen response was impaired in these mice, as 
were inflammatory cytokine levels. Compared to control arthritic littermates, immunized 
GHTg mice showed significantly lower RORγt (retinoic acid receptor-related orphan 
receptor gamma 2), IL-17, GM-CSF, IL-22, and IFNγ mRNA expression in draining lymph 
nodes, whereas there were no differences in IL-21, IL-6, or IL-2 mRNA levels. Data thus 
suggest that Th17/Th1  cell plasticity toward a pathological phenotype is reduced in 
these mice. Exogenous GH administration in arthritic DBA/1J mice reduced the severity 
of established CIA as well as the inflammatory environment, which also shows a GH 
effect on arthritis progression. These results indicate that GH prevents inflammatory joint 
destruction in CIA. Our findings demonstrate a modulatory GH role in immune system 
function that contributes to alleviating CIA symptoms and underlines the importance of 
endocrine regulation of the immune response.
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inTrODUcTiOn
Growth hormone (GH) is secreted by the anterior pituitary in vertebrates. Although initially 
defined as a major stimulant in somatic growth control, it is in fact a pleiotropic hormone that 
affects many physiological functions. GH regulates bone and muscle mass (1, 2), carbohydrate, fat, 
and protein metabolism (3), sexual maturation (4), and insulin resistance (5). Several in vitro and 
in vivo studies also demonstrate GH involvement in immune regulation, and the GH receptor is 
expressed by several leukocyte subpopulations (6). GH mediates thymic development (7), promotes 
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T cell engraftment in severe combined immunodeficiency mice 
(8), improves B cell responses and antibody production (9, 10), 
and modulates NK  cell (11) and macrophage activity (12) as 
well as in  vivo Th1/Th2 and humoral immune responses (13). 
Some reports describe beneficial effects of GH administration in 
autoimmunity. GH administration and neutralization of TNFα 
reduce mucosal inflammation in experimental colitis (14); by 
altering tolerization mechanisms such as the cytokine environ-
ment, macrophage polarization, activation of the suppressor 
T cell population, and Th17 cell plasticity, GH also reduces type I 
diabetes development (15).
Rheumatoid arthritis (RA) is the most prevalent inflamma-
tory autoimmune disease worldwide. Its main clinical feature is 
chronic inflammation in joints, associated with bone and cartilage 
destruction (16). The RA spectrum and disease progression are 
governed by immune, genetic, and environmental factors (17). 
Its origin nonetheless lies in an inappropriate inflammatory 
reaction derived from deregulation of the adaptive and/or innate 
branches of the immune response. During RA development, 
there is active proliferation of endothelial cells and synovial fibro-
blasts; the synovium displays features of chronic inflammation, 
including massive leukocyte infiltration of innate (macrophages, 
NK, and dendritic cells; DC) and adaptive (CD4+ T and B cells) 
immune response cells (16).
Using collagen-induced arthritis (CIA) as a model of RA, 
we observed that GH transgenic (GHTg) mice were protected 
against disease development, whose onset was delayed and sever-
ity reduced. Our data demonstrated an inhibitory role of GH in 
the induction phase of the disease. The anti-collagen response 
was severely impeded in GHTg mice, as was the synthesis 
of inflammatory cytokines, suggesting impairment of Th17/
Th1  cell plasticity toward a pathological phenotype. GH also 
modulated the CIA progression phase, shown by reduced sever-
ity of established disease in collagen-immunized DBA/1J mice 
following exogenous GH administration. Our data demonstrate 
that GH administration ameliorates CIA symptoms pointing out 
an important role of this hormone tuning the immune response. 
Altogether, our results underline the interrelationship between 
the endocrine and the immune systems that regulate the immune 
response and support a potential use of endogenous endocrine 
mediators for the treatment of inflammatory and autoimmune 
diseases.
MaTerials anD MeThODs
Mice
Mice transgenic for bovine GH (bGH) under the control of the 
phosphoenolpyruvate carboxykinase promoter on a C57BL/6J 
background (18) were maintained by continuous backcrosses 
on C57BL/6J females. 35 transgenic mice (GHTg) and 33 
control littermates (10–14 weeks old) were used, with matched 
sex ratios in each experiment. DBA/1J mice (50 males) were 
obtained from Charles River Laboratories International. Three 
OVA-specific TCR-transgenic mice (OT-II) were donated by 
Dr. C. Ardavín (Centro Nacional de Biotecnología, Madrid, Spain). 
Mice were handled according to national and European Union 
guidelines, and experiments were approved by the Comité Ético 
de Experimentación Animal, Centro Nacional de Biotecnología/
CSIC and the Regional Government (PROEX 250-16).
cia induction and Treatment
Two-month-old GHTg mice, control littermates, or DBA/1J 
mice were immunized intradermally (i.d.) at the tail base with 
an emulsion of chicken type II collagen (CII) in citrate buffer and 
Freund’s complete adjuvant (19). Arthritis was assessed daily by 
scoring each limb on a 0–4 scale, where 0 = normal, 1 =  ery-
thema and mild swelling confined to the tarsals or ankle joint, 
2 = erythema and mild swelling extending from the ankle to the 
tarsals, 3 = erythema and moderate swelling extending from the 
ankle to metatarsal joints, and 4 = erythema and severe swelling 
encompassing the ankle, foot, and digits, or ankylosis of the limb, 
yielding a maximum score of 16 per mouse. In some cases, on 
appearance of the first signs of CIA (score ~2 = day 0), affected 
DBA/1J mice were separated into two groups; one group received 
a daily subcutaneous (s.c.) rhGH injection (2  µg/ml, 200  µl, 
Genotonorm, Pfizer) until day 9 and the other received only PBS 
as control. Clinical scores (Cst) were re-evaluated daily.
histochemistry
At the end of the experiments, the score was monitored and paws 
removed, fixed in 4% formalin, decalcified with 500 mM EDTA 
(Sigma) at 4°C, and paraffin embedded. Sections (7-µm thick) 
were hematoxylin/eosin-stained. When needed, safranin O/light 
green and fast green or TRAP staining were carried out using a 
leukocyte acid phosphatase staining kit (Sigma-Aldrich). Sections 
were analyzed in an Olympus BX51 microscope equipped with a 
digital camera (Olympus DP70).
cell Purification and Flow cytometry
To prepare single-cell suspensions, spleens and lymph nodes 
(LNs) were harvested and minced on a 40-µm nylon mesh in 
RPMI 1640 medium (Lonza) supplemented with 10% fetal 
bovine serum (FBS), 2 mM l-glutamine, and 50 µg/ml penicillin/
streptomycin. Erythrocytes were lysed with VersaLyse (Beckman 
Coulter). Single-cell suspensions of lymphoid organs or blood 
leukocytes were prepared and blocked with anti-CD16/32 (BD 
Pharmingen) to impede nonspecific Fc-mediated antibody 
binding. Samples were stained with antibody conjugates by a 
standard procedure, using FITC anti-CD25, FITC anti-CD11b, 
SPRD (Spectral Red) anti-Gr1 (Pharmingen), SPRD anti-CD4 
and PE-Cyan5 anti-F4/80 (BM8) (eBiosciences), FITC anti-CD8, 
-CD69, -CD45, APC (allophycocyanin) anti-B220 (Beckman 
Coulter), and PE (phycoerythrin) anti-CD86 (BioLegend). 
FoxP3, IL-10, IL-17, GM-CSF, IFNγ, and TNFα expression was 
determined after permeabilization and intracellular staining 
with a PE-labeled antibody (FoxP3 staining set; eBiosciences), 
FITC-labeled antibody to IL-10 (JES516E3, Pharmingen) and to 
GM-CSF (MP1-22E9, eBiosciences), and PE-labeled antibody to 
IL17 (TC11-18H10, Pharmingen), PE-Cyan7-labeled antibody 
to TNFα (MP6-xt3, eBiosciences), and APC-labeled antibody to 
IFNγ (XMG1.2, R&D Systems).
For in  vitro characterization of CD4+ and CD8+ T  cell sub-
populations in the LNs of GHTg and control mice, 1 × 106 cells/ml 
were cultured (4 h, 37°C, 5% CO2) in RPMI supplemented with 
Table 1 | PCR primer sequences.
gene name genebank accession number sequence position Primers sequence
β-Actin NM007393 694–831 for  
rev
5′-AGAGGGAAATCGTGCGTGAC-3′
5′-CAATAGTGATGACCTGGCCGT-3′
Tbx21 NM009322 474–574 for  
rev
5′-CACTAAGCAAGGACGGCGAA-3′
5′-CCACCAAGACCACATCCACA-3′
RORγt NM011281 808–908 for  
rev
5′-GAAGCTGGGAGCTATGCAGG-3′
5′-TGGCTACGATGCAGCAAGGAG-3′
Foxp3 AY357713 929–1029 for  
rev
5′-TGCTGATGGGAGGAGATGTCT-3′
5′-TTTCTTTCAGGGACAGCCTGTT-3′
IFNγ K00083 929–1029 for  
rev
5′-TGCTGATGGGAGGAGATGTCT-3′
5’-TTTCTTTCAGGGACAGCCTGTT-3′
IL-2 NM008366 252–352 for  
rev
5′-GAAACTCCCCAGGATGCTC A-3′
5′-GCCGCAGAGGTCCAAGTTC-3′
IL-10 NM010548 113–218 for  
rev
5′-TGACTGGCATGAGGATCAGC-3′
5′-AGTCCGCAGCTCTAGGAGCA-3′
IL-17A NM010552 338–398 for  
rev
5′-GAAGCTCAGTGCCGCCA-3′
5′TTCATGTGGTGGTCCAGCTTT-3′
IL-21 NM021782 510–581 for  
rev
5′-AAGATTCCTGAGGATCCGAGAA-3′
5′-GCATTCGTGAGCGTCTATAGTGTC-3′
IL-22 NM016971 204–271 for  
rev
5′-TACATCGTCAACGCACCTTT-3′
5′-CGGACGTCTGTGTTGTTAT-3′
IL-6 NM031168 187–327 for  
rev
5′-GAGGATACCACTCCCAACAGACC-3′
5′-AAGTGCATCATCGTTGTTCATACA-3′
TGFβ1 NM011577 1697–1790 for  
rev
5′-GGAGAGCCCTGGATACCAAC-3′
5′-CAACCCAGGTCCTTCCTAAA-3′
CCL21a NM001193667 250–378 for  
rev
5′-ATCCCGGCAATCCTGTTCTC-3′
5′-GGGGCTTTGTTTCCCTGGG-3′
CCL20 NM001159738 107–224 for  
rev
5′-CTGCTGGCTCACCTCTGCA-3′
5′-CATCGGCCATCTGTCTTGTG-3′
CXCL12 NM021704 244–344 for  
rev
5′-AGCCAACGTCAAGCATCTGA-3′
5′-TCGGGTCAATGCACACTTGT-3′
Primer sequences employed for PCR detection of several factors involved in the differentiation and function of Th17, Th1, or Treg subsets, as well as for β-actin (housekeeping gene).
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10% FBS, 50  ng/ml PMA (Sigma), and 500  ng/ml ionomycin 
(Sigma). For intracellular staining, 2.5  µM monensin (Sigma) 
was added after 60 min of culture. Cells were then fixed with 2% 
paraformaldehyde and permeabilized with 0.2% Saponin (Sigma) 
prior to be stained with the appropriated antibodies.
For the analysis of LNs in GH-treated arthritic DBA/1J mice 
and controls, 5 × 106 cells/ml were cultured (5 h, 37°C, 5% CO2) 
in RPMI supplemented with 10% FBS, 5  ng/ml PMA (Sigma), 
500 ng/ml ionomycin (Sigma), 25 µM TAPI-1 (Enzo), GolgiStop 
and GolgiPlug (BD Pharmingen). Cells were fixed and stained 
according to the manufacturer’s instructions. For intracellular 
staining of FoxP3, we employed the FoxP3/transcription factor 
staining buffer set (eBiosciences) and we used the Cytokine BD 
kit BD Pharmingen for the rest of cytokines evaluated.
When required, cells isolated from LNs were cultured (48 h, 
37°C, 5% CO2) in plates coated with anti-CD3 (100 ng/ml, 4 h, 
37°C; clone 145-2C11, BioLegend). IFNγ and IL-7 levels were 
determined in culture supernatants using the ELISA MAX sets 
(BioLegend).
When necessary, murine naïve B  cells were purified from 
spleen using mouse pan-B Dynabeads (Invitrogen). Batches 
with >95% purity were activated with 5 µg/ml goat anti-mouse 
IgM Ab (Jackson ImmunoResearch; 6 h, 37°C) or 5 µg/ml LPS 
(lipopolysaccharide from Escherichia coli serotype 055:B5; Sigma; 
6  h, 37°C), alone or with exogenous recombinant human GH 
(rhGH, 5 µg/ml, Genotonorm; Pfizer). Stained samples as above 
were analyzed on a flow cytometer (Cytomics FC 500; Beckman 
Coulter). FACS data were analyzed using the FlowJo (FlowJo 
LLC) and CytoSpec (Germany) software.
bone Marrow Dendritic cell (bM-Dc) 
Differentiation
Bone marrow dendritic cell from GHTg or control littermates were 
obtained from bone marrow cell suspensions treated with erythro-
cyte lysis buffer and cultured in 150-mm Petri dishes in complete 
RPMI 1640 medium supplemented with 10% FCS and 20 ng/ml 
recombinant granulocyte–macrophage colony-stimulating factor 
(PeproTech) (20). Immature BM-DC were collected on day 8 and 
purity evaluated by flow cytometry using anti-CD11c-FITC and 
-MHCII-PE Ab (BD Pharmingen). Batches of >95% purity were 
used for maturation with LPS (1 µg/ml, 12 h, 37°C).
In Vitro induction of immune synapse (is) 
Formation between Dc and cD4 T cells
Immune synapse formation between mouse BM-DC and 
OT-II CD4+ T  cells was induced as reported (21, 22). Briefly, 
mature BM-DC (1  µg/ml LPS, 12  h, 37°C) were loaded with 
FigUre 1 | GHTg mice are resistant to collagen-induced arthritis. One 
representative experiment is shown of three performed (n = 11 mice/group). 
(a) Cumulative incidence of arthritic symptoms in wild-type (wt) and GHTg 
mice after immunization with chicken type II collagen. (b) Clinical scores in 
affected wt and GHTg mice. Data shown as mean ± SEM (Student’s t-test, 
*p ≤ 0.05). Two-way ANOVA shows significant differences for time 
(p = 0.0217) and genotype (p < 0.0001) factors.
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OVA323–339-peptide (5 µM, 30 min, 37°C; GenScript) and mixed 
in complete medium (RPMI 1640, 10% FCS) with CD4+ T cells 
(1:5 DC:CD4+ T cells) from OT-II mouse spleen and LNs, puri-
fied with a mouse T cell negative isolation kit (MACS; Miltenyi 
Biotec; T cell purity was routinely >97%). Cells were centrifuged 
(120 ×  g, 2  min) in a conical tube and incubated in complete 
medium (15–30 min, 37°C) to foster IS formation.
T cell Proliferation
OT-II CD4+ T cells were labeled with CellTrace Violet (0.5 µM, 
30 min, 37°C; Molecular Probes) and added to plates containing 
OVA peptide-loaded BM-DC (3 × 104 DC/6 × 104 T cells). Cells 
were co-cultured in RPMI 1640 with 10% FCS (24, 48, or 72 h), 
and proliferation determined by flow cytometry using dye dilu-
tion evaluation in a Gallios flow cytometer (Beckman Coulter). 
The percentage of dividing cells was calculated using the FlowJo. 
When needed, 5 µg/ml rhGH was added.
enzyme-linked immunoassay
Microtiter plates were coated with chicken type II collagen in PBS 
(5 µg/ml; 90 min, 37°C). After blockade of free protein-binding sites 
with 0.5% BSA/PBS, plates were incubated with serial dilutions of 
serum samples from immunized mice, followed by peroxidase-
labeled subclass-specific rabbit anti-mouse antisera (Dako).
semiquantitative real-Time Pcr
cDNA sequences were obtained from the GenBank database. 
PCR primers were designed from the cDNA sequences using 
Primer-BLAST software (Table  1). RNA (5  µg) was used for 
reverse transcription. cDNA was obtained by SuperScript II 
reverse transcriptase (Invitrogen). cDNA was then amplified 
by PCR using Power SYBR Green PCR Master Mix (Applied 
Biosystems) and 0.3 µM of primers. Triplicate samples were quan-
tified using the ABI Prism HT7900 sequence detection system 
(Applied Biosystems). For relative quantification, we used the 
equation 2−ΔCt. Each sample was normalized with β-actin (∆Ct) 
and the respective basal levels in the spleen of wild-type (wt) mice 
(ΔΔCt).
statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0 
software (GraphPad). Unpaired Student’s t-test, Mann–Whitney 
U-test, and two-way ANOVA were used as indicated (in all cases, 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
resUlTs
ghTg Mice are Protected against cia
To analyze the effect of GH in immune response regulation, we 
tested its effect in a murine model of CIA on a mouse strain trans-
genic for bGH under the control of the rat phosphoenolpyruvate 
carboxykinase promoter; these mice showed constant circulating 
GH (~5  μg/ml) (18). The CIA model allows the study of the 
priming phase of the disease, which consists of activation of the 
collagen type II-specific immune response as well as the inflam-
matory effector phase, characterized by local inflammation, and 
cartilage and joint destruction (23). GHTg mice were partially 
protected, and developed arthritis at a lower incidence compared 
to wt arthritic control littermates (GHTg vs. wt, 0 vs. 45% at day 
30, 20 vs. 70% at day 35). The GHTg mice also showed delayed 
disease onset (GHTg, day 33 vs. wt, day 21) (Figure 1A) concomi-
tant with a marked decrease in CIA severity (Figure 1B), as shown 
by evaluation of the incidence and clinical score. Consistent with 
these results, histopathological examination at day 30 highlighted 
a marked reduction in synovial inflammation, pannus formation, 
erosion of articular cartilage in GHTg vs. control arthritic mice, 
and presence of osteoclasts in the joints of wt mice (Figures 2A–C).
In accordance with a previous report (19), we detected low 
IgG1 levels in wt arthritic mice, while IgG2 was the predominant 
isotype in late disease phases (day 25). IgG1 and IgG2 responses 
were nonetheless equally reduced in GHTg mice (Figure 2D). The 
lesser severity of CIA symptoms in GHTg mice was associated with 
changes in anti-collagen type II antibody levels. Anti-collagen IgM 
and IgG antibody levels were significantly lower in GHTg mice 
relative to wt arthritic mice, which suggests that GH triggered 
protection during the induction phase of the disease (Figure 2D).
As reported (13), flow cytometry analysis showed that in basal 
conditions compared to controls, GHTg mice had a significantly 
higher proportion of B220+ cells in LNs and reduced percentage 
of CD4+ and CD8+ T cells, whereas no variations were found in 
the percentage of immune cell populations either in blood or in 
FigUre 2 | Histological comparison in cartilage and bone of collagen-
immunized wild-type (wt) and GHTg mice. Representative images at day 30 
post-inoculation. (a) Acid phosphatase reaction in formaldehyde-fixed 
paraffin embedded joint sections showing osteoclasts (arrows).  
(b) Hematoxylin/eosin staining shows pannus only in the wt sample.  
(c) Safranin-light green staining shows no evidence of cartilage degradation 
in the GHTg mouse sample. (a,b) Original magnification, 2.5× (bar, 1 mm);  
(c) 5× (left; bar, 500 µm), 10× (right; bar, 200 µm). (D) Isotype-specific ELISA 
to detect anti-chicken collagen II antibodies in sera from the immunized mice. 
Individual values are shown for sera diluted 1/200, except for IgG2b 
(1/1,000). Tukey boxplot showing median and 1.5 interquartile range. 
Student’s t-test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
Table 2 | Distribution of cell populations in wild-type (wt) and GHTg mice.
spleen Peripheral lymph nodes (lns) blood
wt ghTg wt ghTg wt ghTg
CD8+ 20.4 ± 5.8 17.6 ± 4.5 32.6 ± 0.9 21.5 ± 1.7** 15.7 ± 0.5 11.3 ± 0.4
CD4+ 17.4 ± 2.1 12.8 ± 2.1 32.3 ± 1.0 25.1 ± 1.5* 16.3 ± 1.9 13.6 ± 2.0
B220+ 68.6 ± 2.2 66.1 ± 2.1 28.6 ± 2.2 48.8 ± 0.6*** 46.7 ± 1.8 53.8 ± 2.4
CD11b+ 14.9 ± 1.0 16.0 ± 0.2 10.7 ± 2.8 13.2 ± 3.2 29.8 ± 6.4 20.7 ± 2.2
GR1+ 1.3 ± 0.3 2.6 ± 0.5 0.3 ± 0.1 0.6 ± 0.3 8.4 ± 0.8 11.4 ± 1.7
Distribution of cell populations in blood, spleen, and peripheral LNs of 12-week-old wt and GHTg mice. Numbers correspond to the percentage of positive cells ± SD indicated 
(n = 3). Bold numbers highlight significant differences between GHTg and control mice, as indicated.
Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
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spleen (Table  2). When evaluated different subpopulations of 
T cells we did not detect differences (Table 3). Previous reports 
suggest a role for GH in modulating the immune response 
(10, 12, 13, 15); we thus characterized immune cell subsets in 
blood and peripheral LNs from collagen-immunized GHTg 
mice and wt littermates. Flow cytometry analysis showed that, 
compared to controls, immunized GHTg mice had a significantly 
larger number of B220+ cells in peripheral LNs (Table  4). In 
agreement with a previous report (15), GH did not affect in vitro 
B  cell activation by either anti-mouse IgM antibodies or LPS 
(Figure  3), which rules out intrinsic in  vitro activation defects 
of GHTg mouse B  cells. The immunized GHTg mice also had 
significant lower percentage of CD4+IFNγ+ and of CD8+IFNγ+ 
cells and a marked tendency to higher proportion of CD4+FoxP3+ 
cells compared to control littermates (Table 5). These data suggest 
differences in T cell polarization between both groups of mice.
To evaluate the GH effect on antigen presentation to T cells, we 
treated BM-DC derived from GHTg mice or wt controls in vitro 
with LPS and loaded the cells with OVA323–339-peptide. Cells were 
then mixed, alone or with rhGH, with OT-II mouse CD4+ cells 
purified by negative selection and labeled with CellTrace Violet. 
Flow cytometry detection of cell tracker dilution after 48 and 
72 h co-culture showed similar OT-II T cell proliferation in all 
conditions analyzed (Figure 4A); no differences were observed 
in CD4+ T  cell activation markers (CD25, CD69, CD62L) 
(Figures  4B–D). These results suggest that antigen-presenting 
cells from GHTg and control littermates have similar antigen-
presenting capacity to CD4+ T  cells and that exogenous rhGH 
does not affect responder CD4+ T cell proliferation.
gh regulates the Th17 and Th1 Profiles
Rheumatoid arthritis has long been considered a Th1-mediated 
disease, but considerable evidence shows a key role for proin-
flammatory Th17  cells in inflammation and joint destruction 
(24, 25). IL-17 levels are high in serum and synovial tissue of RA 
patients (26). IL-17-deficient allogenic bone marrow transplant 
in mice prevents CIA and reduces disease severity (27). We 
thus characterized the Th17 profile in CIA mouse LNs at day 37 
post-inoculation. Immunized GHTg mice showed a significant 
reduction in RORγt, IL-17, GM-CSF, and IL-22 mRNA expres-
sion compared to control arthritic littermates, whereas there were 
no differences in IL-21, IL-6, or IL-2 mRNA levels in peripheral 
LNs (Figure  5A). These results indicate that GH reduced the 
pathogenic profile of the Th17 response. In arthritic GHTg vs. wt 
FigUre 3 | Growth hormone (GH) does not alter B-cell activation in vitro. Splenic B cells from wild-type (wt) and GHTg mice were unstimulated or incubated (6 h, 
37°C) with anti-IgM antibody or LPS alone or with exogenous rhGH (5 µg/ml). The activation level was determined using anti-CD69 and anti-CD86 mAb in flow 
cytometry. One representative experiment of three is shown.
Table 4 | Distribution of cell populations in immunized wild-type (wt) and GHTg mice.
spleen Peripheral lymph nodes (lns) Mesenteric lns blood
wt ghTg wt ghTg wt ghTg wt ghTg
CD3+ 33.7 ± 1.2 33.8 ± 4.8 51.7 ± 13.2 43.2 ± 9.7 64.8 ± 3.3 56.1 ± 6.4 28.2 ± 4.2 22.4 ± 2.2
CD4+ 19.4 ± 2.6 22.5 ± 10.7 27.9 ± 6.5 25.9 ± 5.2 38.2 ± 1.7 36.7 ± 4.1 15.3 ± 2.5 12.7 ± 1.1
CD8+ 19.0 ± 1.3 17.9 ± 3.4 23.4 ± 6.5 16.4 ± 4.9 28.9 ± 3.1 21.5 ± 4.5 10.5 ± 4.0 8.5 ± 0.9
B220+ 54.1 ± 5.3 50.8 ± 6.7 35.4 ± 4.7 54.0 ± 8.3* 34.8 ± 3.7 41.7 ± 7.0 65.2 ± 3.9 68.8 ± 3.9
NK1+ 1.9 ± 0.7 1.5 ± 0.5 0.9 ± 0.3 1.0 ± 0.2 0.8 ± 0.1 1.2 ± 0.1 2.5 ± 0.8 2.6 ± 0.9
CD11b+ 5.3 ± 1.9 6.6 ± 3.7 4.7 ± 1.3 6.5 ± 2.0 7.7 ± 2.3 13.1 ± 2.0 20.5 ± 5.6 24.4 ± 7.2
GR1+ 5.5 ± 1.5 7.5 ± 3.8 6.6 ± 1.3 8.2 ± 0.9 8.0 ± 1.6 12.4 ± 1.0 15.8 ± 4.0 17.5 ± 5.0
F4/80+ 4.7 ± 0.8 6.1 ± 2.0 0.9 ± 0.4 1.1 ± 0.8 2.9 ± 1.4 5.4 ± 0.8 6.7 ± 3.0 9.8 ± 5.8
Distribution of cell populations in blood, spleen, and peripheral LNs of collagen type II-immunized wt and GHTg mice. Numbers correspond to percentage of positive cells ± SD 
values (n = 3). Bold numbers highlight significant differences between GHTg and control mice, as indicated.
Student’s t-test, *p < 0.05.
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mice, we also found significantly lower levels of Tbx21 mRNA, 
the master regulator of the Th1 subset (Figure 5B). These data 
correlated with a marked reduction in IFNγ mRNA levels in 
GHTg relative to wt mice. We also found significant higher 
levels of TGFβ in GHTg mice (Figure 5A), although we did not 
observed differences in FoxP3 and in IL-10 mRNA levels between 
the two mouse groups (Figure 5B). We nonetheless observed a 
Table 3 | Distribution of CD3+/CD4+ and CD3+/CD8+ cell populations in non-
immunized wild-type (wt) and GHTg mice.
Peripheral lymph nodes (lns)
wt ghTg
CD4+ Foxp3+ 10.75 ± 1.48 16.83 ± 2.17
IFNγ+ 21.10 ± 6.93 21.40 ± 1.85
IL-17+ 0.335 ± 0.205 1.113 ± 0.340
CD8+ IFNγ+ 16.30 ± 5.66 23.73 ± 9.59
IL-17+ 0.385 ± 0.262 0.758 ± 0.299
Distribution of cell populations in peripheral LNs of wt and GHTg mice. Numbers 
correspond to percentage of positive cells ± SD values (n = 3).
tendency to higher FoxP3/RORγT ratio when comparing GHTg 
(0.59 ± 0.06) with controls (0.32 ± 0.05). These results confirmed 
the milder disease observed in GHTg mice and support the 
beneficial effect of GH.
Therapeutic gh administration reduces 
Disease severity in cia Mice
We used the CIA model in DBA/1J mice to assess the potential 
therapeutic use of GH administration. Arthritis was induced 
by i.d. injections of collagen type II into 2-month-old mice. On 
appearance of the first CIA signs (score ~2 = day 0), affected mice 
were divided into two groups; one received a daily s.c. GH injec-
tion until day 10 and the other received PBS as control. CIA pro-
gression was delayed in GH-relative to PBS-treated arthritic mice 
(Figure 6A); this effect was observed as early as 2 days after initia-
tion of treatment and reached a maximum at 6 days. The number 
of affected paws increased with time in PBS-treated arthritic 
mice, but GH-treated mice showed no variation (Figure 6B). GH 
treatment did not alter anti-collagen IgM and IgG antibody levels 
in arthritic DBA/1J mouse serum (Figure 6C). These data suggest 
FigUre 4 | Growth hormone (GH) affects neither bone marrow dendritic cell (BM-DC) antigen presentation nor T cell activation. (a) OT-II mouse CD4+ splenocytes 
were stained with CellTrace Violet and co-cultured with bone marrow-derived wild-type (wt) or GHTg dendritic cells (BM-DC), alone or with rhGH. Cells were 
harvested after 48 or 72 h and analyzed by flow cytometry. A representative experiment is shown of three performed. wt cells at t = 0 were used as control. CD4+ 
cells from similar co-cultures were analyzed by flow cytometry at 0, 6, 12, and 24 h for activation markers CD25 (b), CD69 (c), and CD62L (D). One representative 
experiment is shown of three performed.
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Table 5 | Distribution of CD3+/CD4+ and CD3+/CD8+ cell populations in 
immunized wild-type (wt) and GHTg mice.
Peripheral lymph nodes (lns)
wt ghTg
CD4+ Foxp3+ 10.80 ± 1.99 13.55 ± 0.35
IFNγ+ 14.77 ± 3.74 10.45 ± 2.76*
IL-17+ 0.2267 ± 0.0115 0.3850 ± 0.0636
CD8+ IFNγ+ 19.23 ± 2.003 13.45 ± 0.2121*
IL-17+ 0.3667 ± 0.155 0.28 ± 0.0424
Distribution of cell populations in peripheral LNs of collagen type II-immunized wt and 
GHTg mice. Numbers correspond to percentage of positive cells ± SD values (n = 3). Bold 
numbers highlight significant differences between GHTg and control mice, as indicated.
Student’s t-test, *p < 0.05.
that, in addition to its role in the induction phase of the disease, 
GH can hinder experimental arthritis progression.
Growth hormone treatment reduced RORγt, IL-17, and 
IL-22 mRNA expression in LNs at day 10 (Figure 6D). We also 
detected lower Tbx21 and IFNγ levels in GH- compared to PBS-
treated CIA mice, whereas IL-10 levels increased (Figure  6D). 
When, in the same samples, the expression levels of chemokines 
were evaluated, we found in GH-treated mice, similar levels of 
homeostatic chemokines, CCL21 and CXCL12, and a significant 
reduction of the inflammatory chemokine CCL20 (Figure S1 
in Supplementary Material). CCL20 is a key chemokine for 
Th17  cell movement (28). These data, in line with the results 
for GHTg arthritic mice, suggested that exogenous rhGH 
promoted Th17  cell repolarization to a non-pathogenic profile 
or, alter natively, blocked Th17 polarization to a Th1 pheno-
type. The analysis of these cells in the LNs of GH-treated CIA 
mice confirmed these observations. Among CD4+ T  cells, GH 
treatment reduced the number of IL-17-expressing cells from 
0.040 ± 0.02 × 106 to 0.003 ± 0.01 × 106 cells and of GM-CSF 
expressing cells from 0.14 ± 0.02 × 106 to 0.06 ± 0.02 × 106 cells 
in arthritic mice (Figure 7A). In the same experiments, we did 
not detect significant differences in CD4+IFNγ+, CD4+FoxP3+, 
and CD4+IL10+ cells (Figure  7A), although a more detailed 
analysis of the data revealed better regulatory vs. inflammatory 
balance in GH-treated mice (Figure 7B). In accordance, ELISA 
data of cytokine production in culture supernatants of anti-CD3 
activated cells isolated from these LN showed a GH-mediated sig-
nificant reduction of IL-17 (56.33 ± 19.5 pg/ml in GH-treated vs. 
133.85 ± 17.5 pg/ml in controls) and no significant differences in 
IFNγ (863.58 ± 157 pg/ml in GH-treated vs. 974.95 ± 107 pg/ml 
FigUre 5 | Regulation of pathogenic Th17 profile in collagen-induced 
arthritis-induced GHTg mice. (a) Expression of characteristic Th17 
transcription factors and cytokines in peripheral lymph nodes of collagen-
immunized wild-type (wt) and GHTg mice. (b) Expression of transcription 
factors and cytokines associated to Th1 and Treg cell responses. Cytokine 
and chemokine mRNA from arthritic mice was quantified by qRT-PCR. 
Expression is represented as 2−ΔΔCt by normalization to β-actin and the levels 
of each cytokine in spleen of wt mice; mean ± SD, Student’s t-test (n = 12); 
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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in controls) levels compared to controls (Figure 7C). Together, 
these data could determine the anti-inflammatory microenviron-
ment triggered by GH, supporting the therapeutic use of GH.
DiscUssiOn
Chronic inflammation underlies many pathologies of clinical 
importance, including cancer, atherosclerosis, and rheumatic 
diseases. RA is a systemic autoimmune disease characterized 
by non-organ-specific autoantibody production and chronic 
inflammation of synovial tissues, leading to cartilage and bone 
destruction (29). Current therapies, such as cytokine antagonists, 
have shown great promise in treating patients (30), although they 
target the inflammation phase and do not address the initiation 
or resolution phases, that is, those situations in which the balance 
between effector and regulatory responses are disrupted (31).
There is evidence that the immune system is greatly influenced 
by other physiological systems such as the endocrine and neuroen-
docrine systems (32). GH is produced not only by the pituitary 
gland but also by lymphoid organs such as the thymus, the spleen, 
and immune cells in the periphery (33), and the GH receptor is 
expressed on most leukocyte subpopulations (34). Here, we used 
GHTg mice, in which bGH expression is ubiquitous and sustained, 
to analyze GH effects on induction of experimental arthritis. In a 
CIA model, we showed that GHTg mice were partially protected 
compared to wt arthritic littermates. GHTg mice showed delayed 
disease onset and reduced severity. Pannus, cartilage damage, 
and bone resorption were detected only in wt CIA mice, whereas 
we found no sign of joint degradation in GHTg mice at day 30 
post-inoculation. It is well known that GH regulates both bone 
growth and remodeling, although it is unclear whether they are 
effects mediated directly or through IGF-I signaling (35). GH 
modulates both osteoblasts and osteoclasts differentiation and 
activity (36–38). Although we have not analyzed the activity of 
osteoblasts in these mice, we did not detect osteoclasts in the joint 
of collagen-immunized GHTg mice, suggesting that additional 
causes might also contribute to the resistance to arthritis develop-
ment in these mice. A previous report described a spontaneous 
autoimmune-like disorder accompanied by alterations in joints 
of 6-month-old GHTg mice (39). The phenotype in the joints of 
these mice includes disorganization of zonal structure, profound 
alterations in chondrocyte growth/differentiation processes and 
cartilage damage, and it is complemented by increased levels of 
auto-anti-DNA antibodies compared to control littermates. The 
authors, however, rarely found inflammatory infiltrates in syno-
vial tissues indicating that the symptoms detected are more related 
to osteoarthritis related to bone overgrowth rather than to RA. 
We did not observe visceromegaly or changes in weight or in 
length of DBA/1J mice treated with exogenous rhGH, but as it 
is known that GHTg mice develop giantism (18, 40), we cannot 
discard potential side-effects in treatments longer than those used 
in this study.
In accordance with previous observations (13, 15), we detected 
no major differences in any of the circulating immune cell 
populations analyzed in basal conditions, although we observed a 
reduced percentage of CD3+IFNγ+ cells in immunized GHTg mice 
and a marked increase in the percentage of B220+ cells in LNs of 
GHTg mice that was maintained after collagen immunization. We 
nonetheless noticed a marked reduction in anti-chicken collagen 
II antibodies in the sera of immunized GHTg mice, although no 
intrinsic defects were seen in in vitro B cell activation by either 
anti-IgM antibodies or LPS. We also ruled out defects in the abil-
ity of GHTg mouse BM-DC to present antigen and activate T cells 
in  vitro, although the percentage of activated circulating CD4+ 
cells in GHTg mice was lower than in wt arthritic mice.
Autoreactive effector CD4+ T  cells, specifically the IFNγ-
producing Th17/Th1 and non-classical Th1  cells, are associated 
with RA pathogenesis (41). We detected lower IFNγ mRNA 
levels, reduced CD3+IFNγ+ cells and a significant reduction in 
Tbx21 expression in LNs from GHTg with respect to wt arthritic 
mice, which is indicative of the protective role of GH in CIA. 
In these mice, RORγt, IL-17, GM-CSF, and IL-22 mRNA expression 
was also significantly reduced, indicating a reduction in the per-
centage of Th17 cells. A similar expression pattern of cytokines was 
found in GH-treated arthritic DBA/1J mice. Altogether, these results 
suggest that GH maintains a non-pathogenic profile of Th17 cells. 
Th17  cell frequency in peripheral blood correlated directly with 
disease activity. In RA patients, IL-17 levels are similarly increased 
in synovial fluid (42) and contribute to sustain RA chronicity (24). 
FigUre 6 | Effect of therapeutic rhGH administration on arthritic mice. Two-month-old DBA/1J mice were immunized with chicken type II collagen. (a) On 
appearance of the first signs of collagen-induced arthritis (score 2 = treatment day 0), affected mice were separated into two groups; one received a daily rhGH 
injection (2 µg/ml, 200 µl) until day 9, and the other received PBS as control. Clinical scores are expressed as the increase (Δ) from the initial score at t = 0 (score 2). 
Data shown as mean ± SEM. Student’s t-test (n = 12); *p ≤ 0.05. (b) Mean number of affected paws in arthritic mice as in (a). Data shown as mean ± SEM. 
Student’s t-test (n = 12); *p ≤ 0.05. (c) Total anti-collagen type II IgM and IgG were measured in mouse sera by ELISA at the end of the experiment (day 9 
post-treatment) of vehicle- (PBS, black line) or rhGH- (gray line) treated arthritic mice as in (a). The figure shows mean absorbance at 492 nm ± SEM (n = 12).  
(D) Expression of characteristic Th17, Th1, and Treg transcription factors and cytokines in peripheral lymph nodes of mice, normalized to β-actin and expressed as 
2−ΔΔCt. Data shown as mean ± SD. Student’s t-test **p ≤ 0.01; ***p ≤ 0.001.
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There is evidence that Th17 cells are a heterogeneous population 
composed of several pro- and anti-inflammatory subsets (43). We 
also observed increased TGFβ1 and no significant variations in IL-6 
mRNA levels. TGFβ has been associated with the maintenance of 
peripheral tolerance by inhibiting proliferation and differentiation 
of autoreactive T cells (44) and promoting survival of Treg cells (45). 
Although we found no marked differences in the absolute FoxP3 
mRNA levels between GHTg and control mice, immunized GHTg 
mice had a higher FoxP3/RORγT ratio, concurring to previous 
results obtained in a model of diabetes type I in NOD-GHTg mice 
(15). We also found higher ratio of Treg/Th1 cells after GH treat-
ment of arthritic DBA/1J mice compared to controls. IL-6 blockade 
corrects the imbalance between Th17 and Treg cells in patients with 
RA (46). In the absence of IL-6, TGFβ do not generate Th17 cells 
(47–49). Our results thus suggest that GH also favors the immu-
noregulatory responses.
Development of therapeutic strategies that promote regulatory 
mechanisms could allow the establishment of robust, sustained 
resolution of autoimmunity. Moreover, the use of mediators 
endogenously expressed might reduce the associated side-
effects of these treatments. Here, we demonstrate the beneficial 
effect of GH administration at the first signs of arthritis in 
collagen-immunized mice, as well as a clear delay in arthritis 
progression in GHTg compared to control littermates. Several 
rheumatic diseases are characterized by abnormalities in the GH/
IGF-1 paracrine axis (50), and although in adults the relationship 
between serum GH levels and disease progression is debated 
(51), juvenile chronic arthritis patients have reduced GH levels 
(52). In the arthritic DBA/1J model, GH treatment did not affect 
circulating anti-collagen antibody levels, which suggests that 
in this model, GH modulates the progression and resolution 
phases of CIA. The mechanism also involved a GH effect on the 
immune system, as shown by a significant reduction in IFNγ, 
IL-17, and IL-22 mRNA levels in LNs of GH-treated CIA mice, 
with a concomitant increase of IL-10. In contrast of these results, 
IL-10 expression was not elevated in GHTg mice. Although more 
experiments are needed to clarify this discrepancy, differences in 
circulating levels of GH between GHTg and GH-treated DBA/1J 
mice might cause this difference. Whereas GHTg mice have sus-
tained GH levels in sera (~5 µg/ml), wt mice have a pulsatile and 
circadian expression of GH that in our DBA/1J model is modi-
fied by the exogenous administration of the hormone (2 µg/ml). 
Acute responses of GH must thus differ in both mouse models as 
well as how mice are adapted to this circumstance.
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FigUre 7 | rhGH treatment of arthritic DBA/1J mice modulates the inflammatory cytokine profile in lymph nodes (LNs). (a) Quantitation of total number of 
cytokine-producing CD4+ T cells (IL-17, GM-CSF, IFNγ, and IL-10) and regulatory CD4+ T cells (FoxP3+) from a mixture of popliteal and inguinal LN cells. Data are 
the mean ± SEM of two different experiments [controls n = 10; growth hormone (GH)-treated n = 11]. Mann–Whitney U-test *p ≤ 0.05. (b) Ratios of (Tregs + Tr1)/
Th17 cells (left) and of (Tregs + Tr1)/(Th17 + GM-CSF+ CD4+) cells (right) from popliteal and inguinal LNs of DBA/1J mice as in (a). Mann–Whitney U-test *p ≤ 0.05: 
Tregs (CD4+FoxP3+ cells); Tr1 (CD4+IL-10+ cells); Th17 (CD4+IL-17+ cells). (c) Levels of IL-17 and IFNγ in culture supernatants of cells isolated from LNs in (a) and 
activated in vitro (48 h) with anti-CD3 mAb. Data shown as mean ± SD. Student’s t-test *p ≤ 0.05.
Our flow cytometry data on peripheral LNs cells from arthritic 
DBA/1J mice confirmed the effect of GH treatment on the reduction 
number of Th17 and CD4+GM-CSF+ T cells. These data correlated 
with the significant reduction of CCL20 levels found in LNs of mice 
treated with the hormone. CCL20 binds to CCR6, an important 
chemokine receptor for Th17 cells movement (28). CCR6 expression 
by Th17 cells allows their migration across the endothelial barrier in 
several autoimmune diseases such as multiple sclerosis (53) or RA 
(54). The analysis, however, did not show modifications in the num-
ber of CD4+Foxp3+ and CD4+IL-10+ T cells, discarding the participa-
tion of these cells in the increase of IL-10 levels found in GH-treated 
mice. Mesenchymal stem cells (MSCs) are capable of suppressing 
the immune response by inhibiting the maturation of dendritic cells 
and suppressing the function of T  lymphocytes, B lymphocytes, 
and natural killer cells in autoimmune and inflammatory diseases 
(55). In in vitro experiments, MSCs prevent the differentiation of 
naïve CD4+ T cells into Th17 cells and inhibited the production of 
IL-17, IL-22, IFN-γ, and TNF-α by fully differentiated Th17 cells, 
inducing the expression of Foxp3 and IL-10 production (56). 
We observed higher ratio of (Treg + Tr1)/Th17 and of (Treg + Tr1)/
(Th17 + GM-CSF+CD4+) cells in GH-treated arthritic mice com-
pared to controls. Taking into account that MSC express a functional 
GH receptor (57), we can hypothesize that via mobilization from 
their reservoirs and/or by affecting their tropism, GH treatment 
might facilitate the presence of MSC in the LNs, thus favoring IL-10-
mediated regulatory responses. By increasing in the LNs the levels of 
Tregs cells, including CD4+IL10+ Tr1 cells, and triggering Th17 cell 
plasticity toward an IL10-driven anti-inflammatory response, 
adipose-derived MSCs ameliorated established CIA (58). The 
combination between MSC and IL-10-producing Tr1 cells prevents 
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the development of destructive arthritis (59). Although we did not 
observe significant differences in the percentage of F4/80+IL-10+ 
cells between GH-treated DBA/1J and control mice, MSCs can also 
modulate macrophage differentiation toward an anti-inflammatory 
phenotype (60, 61). MSC also induce regulatory DCs in the LNs 
(62). This subpopulation of DCs are characterized by the secretion 
of high levels of IL-10 which is essential for the regulation of the 
immune responses (63). To clarify all these hypotheses, new experi-
ments are actually in progress.
The reduction of Tbx21 levels detected in GH-treated mice 
also suggest that exogenous GH repolarizes Th17  cells to a 
less aggressive phenotype and/or blocks the acquisition of a 
pathogenic profile of this Th17 cells. GH triggers JAK2/STAT5 
phosphorylation (64) and STAT5 controls not only Th2 but also 
Th1 and Th17 differentiation; IL-2 regulates Th1 and Th17 differ-
entiation, which induces STAT5-dependent IL-12Rβ2 and Tbx21 
in Th1 cells and IL-17 expression by Th17 cells (65). We can thus 
hypothesize that GH treatment regulates the expression of genes 
involved in T cell polarization by altering STAT5 phosphoryla-
tion directly or indirectly via SOCS expression regulation.
Our results confirm the importance of GH in regulating 
immune system plasticity, and thus its value as a regulatory mech-
anism that limits the effector response and maintains immune 
system homeostasis. Recombinant human GH improves survival 
and protects against acute lung injury in murine Staphylococcus 
aureus sepsis (66) and protects from acute pancreatitis (67). GH 
decreases gut inflammation and improves or maintains gut barrier 
function, which ultimately inhibits development of inflammatory 
bowel disease (14, 68); co-administration of epidermal growth 
factor and GH-releasing peptide-6, a GH secretagogue, improves 
clinical recovery in experimental autoimmune encephalitis (69). 
GH is thus a candidate for potential treatment of inflamma-
tory disorders and therapy for arthritis and other autoimmune 
diseases.
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